Vychodoslovensky Onkologicky Ustav a.s.

Clinical trials at this hospital-based research site focus mainly on neoplasms, with studies spanning cancers of the prostate, lung, breast, colorectal region, pancreas, biliary tract, melanoma, and head and neck. The research is centered on testing new treatment options and improving outcomes for patients with advanced or hard-to-treat cancers.

• Prostate cancer studies exploring better control of localized, recurrent, and metastatic disease
• Breast cancer research in hormone receptor-positive and HER2-negative advanced disease
• Lung and thoracic cancer trials evaluating new approaches for non-small cell lung cancer
• Colorectal, pancreatic, biliary tract, melanoma, and head and neck cancer investigations

The site’s clinical trials department supports research aimed at assessing treatment effectiveness, extending survival, and refining cancer care for patients across several difficult-to-treat tumor types.

A major part of the research portfolio addresses prostate cancer, including high-risk localized disease, recurrent disease, and castration-sensitive or castration-resistant metastatic forms. These studies are designed to improve disease control and delay progression using new combinations of hormonal and targeted treatments.

• Localized and locally advanced high-risk prostate cancer
• Metastatic castration-sensitive prostate cancer
• Metastatic castration-resistant prostate cancer
• Recurrent or high-risk prostate cancer after definitive treatment

Research here also includes work on androgen receptor–related therapies and other strategies intended to strengthen long-term cancer control while monitoring safety and quality of life.

The site is actively involved in trials for advanced breast cancer, especially hormone receptor-positive and HER2-negative disease. These studies look at whether newer treatment combinations can better slow cancer growth after prior therapy.

• Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
• Estrogen receptor-positive advanced breast cancer
• Metastatic breast cancer with molecular features linked to treatment resistance

This research reflects a strong interest in precision oncology, with the goal of matching treatment more closely to tumor biology and improving progression-free survival.

Several trials at the site focus on colorectal cancer and other gastrointestinal malignancies, including metastatic disease and genetically defined subgroups. The main purpose is to test new treatment approaches that may improve disease control for patients with limited standard options.

• Metastatic colorectal cancer, including BRAF- and KRAS-driven disease
• Untreated metastatic pancreatic ductal adenocarcinoma
• Advanced HER2-expressing biliary tract cancer

These studies combine interest in targeted therapy, immunotherapy, and broader treatment optimization for advanced digestive tract cancers.

Another important research area is non-small cell lung cancer, including metastatic disease and tumors with specific molecular changes such as ROS1 rearrangements or KRAS G12C mutations. The trials are aimed at improving treatment effectiveness and exploring more personalized options for patients with advanced disease.

• Metastatic non-small cell lung cancer
• ROS1-rearranged non-small cell lung cancer
• KRAS G12C-mutant non-small cell lung cancer
• Stage II to IIIB non-small cell lung cancer after surgery or in locally advanced settings

Work in this field also includes studies of immunotherapy and targeted treatment combinations to help delay progression and improve survival outcomes.

In addition to tumor-directed studies, the site conducts research in broader areas such as cancer cachexia and other conditions linked to advanced malignancy. These trials aim to improve symptoms, body weight, and overall well-being for people living with cancer.

• Cancer cachexia and weight loss in advanced cancer
• Supportive care research for fatigue and appetite-related symptoms
• Studies where the disease area is not narrowly specified but remains oncology-focused

This work complements the cancer treatment portfolio by addressing quality of life and symptom management alongside anti-cancer therapy.